Insulet Corporation $PODD Shares Acquired by Empirical Asset Management LLC

Empirical Asset Management LLC increased its position in Insulet Corporation (NASDAQ:PODD) by 6.3% in the second quarter, Holdings Channel reports. The firm owned 2,875 shares of the medical instruments supplier’s stock after purchasing an additional 170 shares during the quarter. Empirical Asset Management LLC’s holdings in Insulet were worth $903,000 as of its most recent SEC filing.

Other hedge funds have also bought and sold shares of the company. Sequoia Financial Advisors LLC boosted its stake in Insulet by 2.3% in the second quarter. Sequoia Financial Advisors LLC now owns 2,017 shares of the medical instruments supplier’s stock valued at $634,000 after acquiring an additional 45 shares during the period. Nissay Asset Management Corp Japan ADV boosted its stake in Insulet by 0.6% in the first quarter. Nissay Asset Management Corp Japan ADV now owns 8,462 shares of the medical instruments supplier’s stock valued at $2,222,000 after acquiring an additional 48 shares during the period. Mather Group LLC. boosted its stake in Insulet by 4.4% in the second quarter. Mather Group LLC. now owns 1,147 shares of the medical instruments supplier’s stock valued at $360,000 after acquiring an additional 48 shares during the period. Brooklyn Investment Group boosted its stake in Insulet by 7.0% in the first quarter. Brooklyn Investment Group now owns 795 shares of the medical instruments supplier’s stock valued at $209,000 after acquiring an additional 52 shares during the period. Finally, Cooper Financial Group boosted its stake in Insulet by 5.7% in the first quarter. Cooper Financial Group now owns 1,079 shares of the medical instruments supplier’s stock valued at $283,000 after acquiring an additional 58 shares during the period.

Wall Street Analyst Weigh In

A number of brokerages have commented on PODD. Weiss Ratings restated a “hold (c)” rating on shares of Insulet in a research note on Wednesday, October 8th. Citigroup reaffirmed a “buy” rating on shares of Insulet in a report on Tuesday, July 8th. Wall Street Zen raised Insulet from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Zacks Research raised Insulet from a “hold” rating to a “strong-buy” rating in a report on Tuesday. Finally, Morgan Stanley reaffirmed an “overweight” rating on shares of Insulet in a report on Thursday, August 7th. One research analyst has rated the stock with a Strong Buy rating, eighteen have assigned a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $348.05.

Insider Activity at Insulet

In related news, SVP Prem Singh sold 687 shares of the business’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $347.49, for a total transaction of $238,725.63. Following the sale, the senior vice president owned 3,456 shares of the company’s stock, valued at $1,200,925.44. The trade was a 16.58% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, SVP Laetitia Cousin sold 797 shares of the business’s stock in a transaction that occurred on Monday, September 8th. The stock was sold at an average price of $348.81, for a total value of $278,001.57. Following the sale, the senior vice president directly owned 3,890 shares in the company, valued at approximately $1,356,870.90. The trade was a 17.00% decrease in their position. The disclosure for this sale can be found here. 0.39% of the stock is owned by insiders.

Insulet Price Performance

Shares of NASDAQ:PODD opened at $316.29 on Friday. Insulet Corporation has a 12 month low of $226.50 and a 12 month high of $353.50. The stock has a market cap of $22.26 billion, a price-to-earnings ratio of 96.14, a PEG ratio of 2.61 and a beta of 1.40. The stock’s 50 day moving average price is $325.99 and its 200 day moving average price is $301.60. The company has a debt-to-equity ratio of 0.64, a current ratio of 2.26 and a quick ratio of 1.81.

Insulet (NASDAQ:PODD) last announced its earnings results on Thursday, August 7th. The medical instruments supplier reported $1.17 EPS for the quarter, topping the consensus estimate of $0.92 by $0.25. Insulet had a return on equity of 23.78% and a net margin of 10.01%.The firm had revenue of $649.10 million for the quarter, compared to analysts’ expectations of $612.31 million. During the same quarter in the previous year, the company earned $0.55 earnings per share. The firm’s quarterly revenue was up 32.9% compared to the same quarter last year. Insulet has set its FY 2025 guidance at EPS. Q3 2025 guidance at EPS. Equities research analysts anticipate that Insulet Corporation will post 3.92 earnings per share for the current fiscal year.

Insulet Company Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.